Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05863858
Status:
COMPLETED
Last Update Posted:
2023-05-18
First Post:
2023-03-25
Brief Title:
Eradication of H Pylori Infection With Moxifloxacin
Sponsor:
Iyad Naeem Muhammad PhD
Organization:
University of Karachi
Study Overview
Official Title:
High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy Randomized Controlled Trials
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RCT
Brief Summary:
The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate safety and patient compliance
Detailed Description:
Patients who were confirmed to be positive for Helicobacter Pylori infection were randomly assigned to the eradication treatments At four weeks after completion of eradication therapy H pylori tests were performed with a Stool antigen test
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None